ANI | Jotup

ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference

Retrieved on:

星期三, 五月 29, 2024

BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows:

Key Points:

BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows:

The rise of artificial intelligence: benefits and risks for financial stability

Retrieved on:

星期二, 五月 28, 2024

Cloud, Algorithm, University of Michigan–Dearborn, Risk, Privacy, Machine learning, Investment, ChatGPT, Trust (social science), Hallucination, United, Risk management, Safe, Artificial intelligence, Figure, Bank for International Settlements, Language, ESRB, ECB, Dangers, OECD, Information technology, Intelligence, Human, Fairness, Finance, International Monetary Fund, Executive order, McKinsey & Company, Publication, Conference, B.2, Crime, ANI, Accountability, Communication, Table, United Nations, Risk assessment, Select committee, Use, Association for Computing Machinery, Synthetic media, TRV, Employment, USD, Federal Reserve, City, Trust, Research, ArXiv, AIS, Attack, Cornell University, Environment, Natural language, Green, Documentation, Bank of England, University, Overalls, Bank statement, Bias, Sound, Bank, Data management, Financial Stability Board, HR, Social media, Artificial Intelligence Act, Data analysis, Brain, Science, Logic, Box, Medical device

The emergence of generative artificial intelligence (AI) tools represents a significant technological leap forward, with the potential to have a substantial impact on the financial system.

Key Points:

The emergence of generative artificial intelligence (AI) tools represents a significant technological leap forward, with the potential to have a substantial impact on the financial system.
Conceptually, AI brings both benefits and risks to the financial system.

ANI Pharmaceuticals Announces the Launch of Kionex® Suspension

Retrieved on:

星期一, 五月 20, 2024

Patient, Suspension, Food, Rectum, IQVIA, RLD, MAT, ANI

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use.

Key Points:

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use.
Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use.
"The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competition to our customers and patients in need.
U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3 million, based on March 2024 moving annual total (MAT) IQVIA data.

Colombia Construction Industry Report 2024: Market to Record Subdued Growth of 1.8% this Year Following 5.2% Decline in 2023 - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on:

星期五, 五月 10, 2024

The Colombian construction industry is expected to record subdued growth of 1.8% in 2024, following an estimated decline of 5.2% in 2023.

Key Points:

The Colombian construction industry is expected to record subdued growth of 1.8% in 2024, following an estimated decline of 5.2% in 2023.
The decline in 2023 is attributed to elevated inflation, high construction material costs and interest rates.
According to the International Monetary Fund, the country's inflation jumped from 3.5% in 2021 to 10.2% in 2022 and remained high in 2023 at 11.4%.
Historical (2019-2023) and forecast (2024-2028) valuations of the construction industry in Colombia, featuring details of key growth drivers.

P10 Reports First Quarter 2024 Earnings Results

Retrieved on:

星期三, 五月 8, 2024

General counsel, EVP, PX, AUM, P10, EPS, Share repurchase, ANI, GAAP, Growth, Video game

DALLAS, May 08, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX) (the “Company”), a leading private markets solutions provider, today reported financial results for the first quarter ended March 31, 2024.

Key Points:

Generated Record Quarterly Revenue of $66.1 Million, a 15% Annual Increase
DALLAS, May 08, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX) (the “Company”), a leading private markets solutions provider, today reported financial results for the first quarter ended March 31, 2024.
“In the first quarter of 2024, P10 delivered record revenues of $66 million and executed against our strategy to generate long-term growth,” said Luke Sarsfield, P10 Chief Executive Officer.
On February 27, 2024, the Board of Directors of the Company increased the share repurchase authorization by $40 million.
In the first quarter, the Company repurchased approximately 3.7 million shares at an average price of $8.15 per share.

WNS Announces Fiscal 2024 Fourth Quarter and Full Year Earnings, Provides Guidance for Fiscal 2025

Retrieved on:

星期四, 四月 25, 2024

WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global digital-led Business Process Management (BPM) solutions, today announced results for the fiscal 2024 fourth quarter and full year ended March 31, 2024.

Key Points:

WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global digital-led Business Process Management (BPM) solutions, today announced results for the fiscal 2024 fourth quarter and full year ended March 31, 2024.
Revenue less repair payments* in the fourth quarter was $325.9 million, increasing 6.9% year-over-year and 3.2% sequentially.
Excluding exchange rate impacts, constant currency revenue less repair payments* in the fiscal fourth quarter was up 5.9% versus Q4 of last year and 2.4% sequentially.
Profit in the fiscal fourth quarter was $12.6 million, as compared to $36.4 million in Q4 of last year and $39.6 million in the previous quarter.

Biopharma Leaders Come Together at Veeva Commercial Summit to Advance Customer-Centric Engagement

Retrieved on:

星期三, 四月 17, 2024

HCP, Commercial, Software, Environment, Novo Nordisk, Idorsia, Marketing, ANI

PLEASANTON, Calif., April 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Genentech, Novo Nordisk, Takeda, and others will be among the keynote speakers at the 2024 Veeva Commercial Summit, May 7-8 in Boston. Commercial and medical affairs professionals will share how they are innovating across content, data and analytics, and customer interactions to advance the future of customer-centric engagement.

Key Points:

Veeva CEO Peter Gassner will headline the opening keynote, sharing how the recent delivery of Veeva Vault CRM fits into Veeva's commercial vision.
"Veeva is committed to commercial execution and bringing life sciences leaders together to share learnings and fresh ideas around commercial strategies and customer engagement to move the industry forward."
One of the largest industry events in North America for commercial and medical affairs professionals, Veeva Commercial Summit will host over 1,700 leaders across more than 100 sessions.
For more on Veeva Commercial Summit, visit: veeva.com/Summit
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

Retrieved on:

星期二, 四月 9, 2024

IQVIA, ANI, RLD, Pharmaceutical industry

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.

Key Points:

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.
"The launch of Baclofen Oral Suspension represents another entry for ANI into a rapidly growing limited competition market.
We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements in a timely manner,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

Retrieved on:

星期四, 四月 4, 2024

Sarcoidosis, ANI, Disease, Incidence, Education, Patient, African Americans, Research, FSR, CAC, Inflammation, Human, Granuloma, Pharmaceutical industry

BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.

Key Points:

BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.
During the month of April, members of the ANI organization are raising awareness of sarcoidosis by wearing “Say Sarcoidosis” pins offered through FSRs National Awareness Campaign, “Say Sarcoidosis.” In addition, ANI members will also be wearing purple on April 13th in honor of “World Sarcoidosis Awareness Day.”
According to the FSR, sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas predominately in the lungs and, to a lesser extent, in other organs of the body.
“We applaud the Foundation for Sarcoidosis Research’s Awareness Campaign – “Say Sarcoidosis” and their ongoing education and support of people who live with sarcoidosis.
“We are grateful for ANI Pharmaceuticals’ commitment to increasing awareness and education about those living with sarcoidosis,” said Mary McGowan, Chief Executive Officer of the FSR.

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

Retrieved on:

星期三, 四月 3, 2024

Encore Boston Harbor, ANI, Piper Sandler Companies

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.

Key Points:

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.
To schedule a 1x1 meeting with the Company, please email [email protected] .